Prostvac in the treatment of prostate cancer: an update

As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …

Breaking news re Prostvac in mCRPC

Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.

This may be good news … or it may not …

Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …

Prostvac VF: a clinical trials update

The Phase III clinical trial of Prostvac VF (rilimogene galvacirepvec/rilimogene glafolivec) in treatment of metastatic, castration-resistant prostate cancer is now fully enrolled, and initial results of this critical trial are expected within the next 12 months. However, … READ MORE …

Financial “hocus pocus” and the (potential) effectiveness of Prostvac VF

If readers come across a report this week suggesting that Barvarian Nordic’s Prostvac VF is likely to fail in the demonstration of effectiveness in its ongoing Phase III trial, you might want to treat that report with some caution. … READ MORE …